An article suggesting thrice weekly doses of cinacalcet could manage certain aspects of bone and mineral metabolism in patients with chronic kidney disease who need treatment with dialysis ...

Conclusions Cinacalcet lowers parathyroid hormone levels and improves calcium–phosphorus homeostasis in patients receiving hemodialysis who have uncontrolled secondary hyperparathyroidism.

Mimpara ® (cinacalcet) was originally approved in the EU in 2004 and is the first oral calcimimetic agent approved by the EC for the treatment of secondary HPT in patients with ESRD on ...

Cinacalcet and etelcalcitide can improve iPTH control, but cinacalcet dosed daily at home is linked to poor adherence rates and etelcalcitide is associated with higher rates of hypocalcemia.

Disorders of mineral metabolism, including secondary hyperparathyroidism, are thought to contribute to extraskeletal (including vascular) calcification among patients with chronic kidney disease. I ...

Cinacalcet is an effective treatment for secondary hyperparathyroidism in patients on dialysis. Until now, no randomized, placebo-controlled, long-term trial has tested this drug in individuals ...

Amgen Receives Positive CHMP Opinion To Expand Use Of Mimpara® (cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Certain Children With End-Stage Renal Disease On Dialysis ...

San Diego, CA - Cinacalcet (Sensipar, Amgen) does not reduce the risk of death or major cardiovascular events among patients with moderate to severe secondary hyperparathyroidism who were on ...

In a position statement on cinacalcet use in children on dialysis, the authors emphasized avoiding hypocalcemia.

Cinacalcet use does not increase the risk for severe gastrointestinal bleeding that leads to hospitalization or death, according to results from an FDA-mandated postmarketing study.

When the patient developed a recurrent parathyroid adenoma she refused surgery and in this case study the authors describe, for the first time, the use of the calcimimetic cinacalcet in a patient ...